Partner Assisted Emotional Disclosure for GI Cancer
The diagnosis and treatment of GI cancer is a traumatic and life-altering event. Many
patients with GI cancer experience significant emotional distress and disruptions in their
social relationships as well as multiple physical symptoms and limitations in physical
activities. There is evidence that cancer patients who are able to confide their feelings
and concerns about the cancer experience with supportive others, particularly their
partners, fare better. patients who are able to discuss cancer openly with their partners
report fewer emotional and physical complaints, and higher levels of self-esteem and
perceived control. However, there are a number of barriers that often inhibit discussion of
cancer-related feelings. The proposed study will examine the effect of a new
partner-assisted emotional disclosure (ED) protocol for patients with GI cancer.
In this study, 200 patients diagnosed with GI cancer and their partners will be recruited to
participate. The couples will be randomly assigned to one of two conditions: 1)
partner-assisted emotional disclosure, or 2) cancer education. Assessment measures will be
collected at evaluations conducted before and after treatment and at 8 weeks post treatment.
All evaluations will be conducted over the phone. Information will also be collected from
the physician and/or the patient's medical record at each of the three evaluations.
Audiotapes of the partner-assisted emotional disclosure sessions will be transcribed and
10-minute segments will be randomly selected and analyzed to assess the extent to which
patients express emotions and partners verbally reflect the partner's feeling in an empathic
manner.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Patient's psychological adjustment
Immediately after treatment and 8 weeks after completion of treatment
No
Laura Porter, Ph.D.
Principal Investigator
Duke University
United States: Institutional Review Board
Pro00011905
NCT00734513
January 2003
March 2008
Name | Location |
---|---|
Duke University Medical Center | Durham, North Carolina 27710 |